Potential Investors Pherin Pharmaceuticals

News & Media

Press Releases and Announcements

December, 2020	Pherin Stockholders Letter Dec. 3, 2020
May, 2020	VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
March 10, 2019	U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
October 22, 2019	Notice to Stakeholders Oct 2019
February 13, 2019	Announcement 2/13/2019
February 12, 2019	Pherin Stockholders Letter Feb 2019
September 13, 2018	Pherin Signs Licensing Agreement with VistaGen Therapeutics
June, 2014	Effect of an Acute Intranasal Aerosol Dose of PH94B on Social and Performance Anxiety in Women With Social Anxiety Disorder